The FDA recently approved a combination of two drugs—abiraterone and the steroid prednisone—for the treatment of castration-resistant prostate cancer (CRPC) in patients who have previously been treated with chemotherapy. Scientists are now testing whether the combination treatment is beneficial for patients who have not been treated with chemotherapy. Interim results indicate that the treatment doubles progression-free survival and increases overall survival from 30.1 months to 35.3 months.
Researchers at the 2013 Genitourinary Cancers Symposium presented the results of two negative phase III studies—READY and VENICE—of targeted agents that failed to increase overall survival when combined with standard first-line chemotherapy docetaxel/prednisone for the treatment of men with metastatic castration-resistant prostate cancer.The two agents are aflibercept and dasatinib.
The London-based company, GSK has stared a phase III trial called “COMBI-AD” that will test the combination of a BRAF and MEK inhibitor, dabrafenib and trametinib in patients with BRAF V600E mutation-positive melanoma who have had surgery to remove their tumors (adjuvant setting). The placebo-controlled trial is testing how long the combo treatment can delay or prevent cancer recurrence in these high-risk patients. Two phase III combination trials are currently ongoing to test the combination versus monotherapy in metastatic BRAF-positive melanoma patients.
Combination of bevacizumab and weekly paclitaxel showed synergitic effects, anti-tumor efficacy and a good toxicity profile for patients with breast cancer but has never been evaluated in non small cell lung cancer (NSCLC). We retrospectively reviewed safety and efficacy of this regimen in metastatic non-squamous NSCLC as fourth-line therapy or beyond.
In our experience, combination of bevacizumab and weekly paclitaxel exhibited acceptable toxicity and had encouraging anti-tumor efficacy as fourth-line treatment or beyond for non-squamous NSCLC patients, supporting further evaluation in larger prospective studies.
We conducted a phase II study of docetaxel in combination with everolimus, a mammalian target of rapamycin (mTOR) inhibitor, for salvage therapy of advanced non–small-cell lung cancer (NSCLC) based on promising preclinical and early-phase clinical data. The combination of everolimus and docetaxel was tolerated well, but the efficacy was relatively modest in an unselected population of patients with NSCLC.
New study suggests the combination of targeting the MEK/ERK and PI3K/mTOR pathways has antitumor activity and could be a therapeutic option in the treatment of NRAS mutant melanoma, for which there are currently no effective therapies.
The combination pemetrexed–carboplatin could be a valuable treatment option in elderly patients, as indicated by this phase II trial. Neutropenia was the most common toxicity. The objective tumor response rate is within the range of data reported for pemetrexed–carboplatin in the general NSCLC population.